Fatiha Chermat

Eprenetapopt Plus Azacitidine in <i>TP53</i>-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM)

Thomas Cluzeau, Marie Sébert, Ramy Rahmé et al. · Journal of Clinical Oncology · 2021 · 268 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

APR-246 Combined with Azacitidine (AZA) in TP53 Mutated Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). a Phase 2 Study By the Groupe Francophone Des Myélodysplasies (GFM)

Thomas Cluzeau, Marie Sébert, Ramy Rahmé et al. · Blood · 2019 · 65 citations

Medicine, Oncology, Pharmacotherapy +16

A randomized phase II trial of azacitidine +/- epoetin-  in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents

Sylvain Thépot, Raouf Ben Abdelali, Sylvie Chevret et al. · Haematologica · 2016 · 62 citations · Full text

Medicine, Hematology, Pharmacology +15

A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure

Marie Sébert, Aline Renneville, Cécile Bally et al. · Haematologica · 2019 · 49 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network

Raphaël Itzykson, Valeria Santini, Sylvain Thépot et al. · Journal of Clinical Oncology · 2022 · 47 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12